Homepage Top Section2

The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial,

The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in

MineBio will supply RoosterBio’s complete platform of products, having already obtained import clearance. This facilitates prompt fulfilment of orders for both research and clinical-grade media solutions focused on

The funding will be used for commercial readiness and the potential US launch of the company’s lead product candidate, AD109, pending approval by the US Food and Drug

The project will enhance Aspect Biosystems’ clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the

This follows the company’s signing of a definitive agreement in October 2025 to acquire the business. The deal adds advanced Protein A chromatography capabilities and Amsphere Protein A

The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. Molecular glues are an emerging therapeutic modality

The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved

The deal is anticipated to close in the second quarter of 2026, subject to standard conditions. The acquisition aims to expand Otsuka’s portfolio in the psychiatric and neurological